Our in vivo results demonstrated that Gln treatment reduced ET release (as indicated by cf-DNA content and MPO activity), decreased lung inflammation (as indicated by reductions in IFN-γ and increases in IL-10 levels), and improved lung morpho-function (as indicated by decreased Est,L and alveolar collapse) in comparison with saline control (ARDS-Sal). This evidence concerns the gene IL10 and acute respiratory distress syndrome.